BE-POSITIVE: B eyond progression after tyrosine kinase inhibitor in E GFR- Positive non small cell lung cancer patients

Highlights • EGFR-TKIs first line treatment evidences impressive objectives response rates. • After 9–12 months acquired resistance to EGFR-TKIs arises. • No optimal therapy has been established beyond EGFR-TKIs progression. • This multicenter study describes patients who progressed to EGFR-TKIs. •...

Full description

Saved in:

Bibliographic Details
Published in:	Lung cancer (Amsterdam, Netherlands)
Main Authors:	Vavalà, Tiziana, Follador, Alessandro, Tiseo, Marcello, Galetta, Domenico, Morabito, Alessandro, Maio, Massimo Di, Martelli, Olga, Caffo, Orazio, Piovano, Pier Luigi, Cortinovis, Diego, Zilembo, Nicoletta, Casartelli, Clelia, Banna, Giuseppe Luigi, Ardizzoia, Antonio, Barzelloni, Maria Luisa, Bearz, Alessandra, Genestreti, Giovenzio, Mucciarini, Claudia, Filipazzi, Virginio, Menis, Jessica, Rizzo, Elisa, Barbieri, Fausto, Rijavec, Erika, Cecere, Fabiana, Bria, Emilio, Spitaleri, Gianluca, Rossi, Antonio, Novello, Silvia
Format:	Journal Article
Language:	English
Published:	2016
Subjects:	Hematology, Oncology and Palliative Medicine Pulmonary/Respiratory ESMO ASCO EGFR mutation EGFR tyrosine kinase inhibitors American Society of Clinical Oncology ECOG Eastern Cooperative Oncology Group second line European Society for Medical Oncology Non Small Cell Lung Cancer first line acquired resistance
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Highlights • EGFR-TKIs first line treatment evidences impressive objectives response rates. • After 9–12 months acquired resistance to EGFR-TKIs arises. • No optimal therapy has been established beyond EGFR-TKIs progression. • This multicenter study describes patients who progressed to EGFR-TKIs. • Treatments, efficacy and safety beyond EGFR-TKIs progression have been described.
ISSN:	0169-5002
DOI:	10.1016/j.lungcan.2016.02.011